Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
- Raised their own holding by 36%.
- 6 different insiders bought in the last 90 days.
Reasons for caution
- Similar past buys beat the S&P 500 only 43% of the time (110 cases); the typical one trailed it by 2.5%.
What happened after this filing
Insider Twins: past buys with the same traits
3+ insiders buying · no CEO or CFO · $1M+ · stock up over 3 months
ALMS Dec 1, 2025 +302.8% vs S&PORGO Dec 3, 2020 +189.2% vs S&PIMVT Oct 7, 2022 +101.2% vs S&PPLCE Feb 16, 2024 -63.4% vs S&PNYC Apr 27, 2022 -62.0% vs S&PONMD Nov 26, 2025 -56.8% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
David Pacitti (a director) bought $100K of OBIO at about $5.00 on Nov 9, 2026, reported to the SEC on Nov 9, 2026. Buys like this beat the S&P 500 43% of the time since 2020, against 46% for all insider buys. We found 3 points that make it worth a closer look and 1 reason for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the OBIO alerts below.
Get this week's insider report
The week's biggest insider buys, every new cluster buy and the stocks to watch, in one printable PDF. Plus the free Monday email.
Check your inbox to confirm, so you get next week's report too.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.